Advertisement
Advertisement
PLX
Protalix BioTherapeutics, Inc. Common Stock
2.72
USDSponsored
-0.03
-1.09%
Sep 25, 15:59 UTC -4
Closed
After-Market
2.71
-0.01
-0.18%
PLX Earnings Reports
Positive Surprise Ratio
PLX beat 21 of 41 last estimates.
51%
Next Report
Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
$12.53M
/-$0.03
Implied change from Q2 26 (Revenue/ EPS)
-37.02%
/-160.00%
Implied change from Q3 25 (Revenue/ EPS)
-29.81%
/-200.00%
Protalix BioTherapeutics, Inc. Common Stock earnings per share and revenue
On Aug 12, 2026, PLX reported earnings of 0.05 USD per share (EPS) for Q2 26, beating the estimate of -0.01 USD, resulting in a 595.05% surprise. Revenue reached 19.90 million, compared to an expected 13.06 million, with a 52.33% difference. The market reacted with a +7.82% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.03 USD, with revenue projected to reach 12.53 million USD, implying an decrease of -160.00% EPS, and decrease of -37.02% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Protalix BioTherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Protalix BioTherapeutics, Inc. Common Stock reported EPS of $0.05, beating estimates by 595.05%, and revenue of $19.90M, 52.33% above expectations.
How did the market react to Protalix BioTherapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 7.82%, changed from $2.43 before the earnings release to $2.62 the day after.
When is Protalix BioTherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for Protalix BioTherapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Protalix BioTherapeutics, Inc. Common Stock is expected to report EPS of -$0.03 and revenue of $12.53M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.